vimarsana.com
Home
Live Updates
Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Saf
Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Saf
Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated with EFX... | June 5, 2023
Related Keywords
United States ,
Americans ,
Kitty Yale ,
Stephen Harrison ,
Pa Fibroscan ,
Christina Tartaglia ,
Nasdaq ,
Exchange Commission ,
Akero Therapeutics Inc ,
Twitter ,
Pinnacle Clinical Research ,
Linkedin ,
Fat Fraction ,
Relative Change ,
Relative Reduction ,
Liver Fat ,
Key Markers ,
Liver Injury ,
Absolute Change ,
Key Cardio Metabolic Biomarkers ,
Conference Call ,
South San ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Report ,
Akero Therapeutics ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
Patients ,
Reated ,
Ith ,
Sfx ,
Or ,
2 ,
Eeks ,
Combined ,
Chieved ,
Relative ,
Reduction ,
N ,
Liver ,
Ompared ,
O ,
Alone ,
F ,
Ith Akro Us00973y1082 ,